Podcasts about Atrial fibrillation

In this episode of The Lead, host Cinzia Monaco, MD, PhD, is joined by Kinan Kneizeh, MD,  and Konstantinos Vlachos, MD, PhD, to discuss "Pulsed Field Ablation Versus Sham to Treat Atrial Fibrillation: The PFA-SHAM Randomized Clinical Trial." The panel examines the trial's sham-controlled evidence for the effects of pulsed field ablation on atrial fibrillation recurrence, quality of life, AF burden, and psychological well-being, while considering placebo effects, study limitations, and the applicability of the findings to clinical practice. Learning Objectives:  1. Describe the design, patient population, endpoints, and key findings of the PFA-SHAM randomized clinical trial. 2. Evaluate the effects of pulsed field ablation compared with a sham procedure on atrial fibrillation recurrence, AF burden, quality of life, and psychological well-being. 3. Assess the trial's limitations, potential placebo effects, and applicability to the management of patients with symptomatic atrial fibrillation. Host: Cinzia Monaco, MD, PhD Guests: Kinan Kneizeh, MD and Konstantinos Vlachos, MD, PhD Disclosures: C. Monaco  • No relevant disclosures K. Kneizeh  • No relevant disclosures K. Vlachos, MD, PhD  • No relevant disclosures  

Your Health Is Your Most Valuable Asset — Are You Actually Protecting It? Your health determines almost everything about the life you get to live — yet how much time do we actually spend protecting it? Today on The Karel Cast, we look at what you can do every day to improve your odds of living a longer, healthier life: exercise, diet, daily habits, preventive care and the medical advances changing how doctors treat disease. We also take a closer look at a procedure more people are hearing about: cardiac ablation. Keith Olbermann and Lionel Richie have both publicly discussed undergoing ablations. But what exactly is an ablation? Why is it performed? What heart rhythm problems can it treat, and who might actually need one? Then we turn to Washington and President Donald Trump's appearance at the United Nations General Assembly. Trump addressed world leaders Tuesday while his administration remains locked in an escalating dispute with CNN, MS NOW and Politico over White House press access. The three organizations are challenging the ban in federal court, while CNN was still able to cover Trump at the U.N. using credentials issued independently by the United Nations. We'll talk about what happened at the U.N., the continuing battle over presidential press access, and what happens when attempts to restrict news coverage end up becoming part of the story themselves. Your body is the one home you never get to move out of. So what are you doing today to protect it? Join the conversation in the comments: What is the single biggest thing you do for your health every day? LIKE this video, SUBSCRIBE to The Karel Cast, and SHARE it with someone who needs to hear this conversation. Support independent media at Patreon: patreon.com/reallykarel Watch and subscribe: youtube.com/reallykarel The Karel Cast is available on Apple Podcasts, Spotify, iHeartRadio, Spreaker and other major podcast platforms, plus TikTok and Instagram. LIVE Monday–Thursday at 10:00 a.m. Pacific. Karel is a history-making broadcaster, entertainer and commentator based in Las Vegas, joined by his little service dog, Ember. #TheKarelCast, #Health, #HealthyLiving, #HeartHealth, #CardiacAblation, #AtrialFibrillation, #AFib, #Longevity, #PreventiveHealth, #Exercise, #Nutrition, #Healthcare, #DonaldTrump, #UnitedNations, #Karel

Your heart has its own rhythm, but what happens when that rhythm becomes too fast, too slow or irregular? This Heart Awareness Month, we turn the focus to arrhythmias as heart rhythm disorders can sometimes go unnoticed. We unpack the signs to look out for, why atrial fibrillation can increase your risk of stroke, how an irregular heartbeat is diagnosed, and the treatment options available to help keep your heart on beat. Early Breakfast with Africa Melane is 702’s and CapeTalk’s early morning talk show. Experienced broadcaster Africa Melane brings you the early morning news, sports, business, and interviews politicians and analysts to help make sense of the world. He also enjoys chatting to guests in the lifestyle sphere and the Arts. All the interviews are podcasted for you to catch-up and listen. Thank you for listening to this podcast from Early Breakfast with Africa Melane For more about the show click https://buff.ly/XHry7eQ and find all the catch-up podcasts here https://buff.ly/XJ10LBU Listen live on weekdays between 04:00 and 06:00 (SA Time) to the Early Breakfast with Africa Melane broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3N Subscribe to the 702 and CapeTalk daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Anticoagulation for atrial fibrillation with intermediate stroke risk: The SINGLE-AF trial

Cancer rise in younger adults may be explained by accelerated cellular aging; “Quadriceps activation failure” may explain common waking difficulty following successful knee replacement; Is “Calocurb” a good natural alternative to GLP-1 drugs? New study claims 4 to 6 servings of whole grains may be the key to heart health—but doubts arise due to its authorship in Iran, a hotbed of scientific research fraud; Splenda back in the crosshairs as new evidence points to genetic damage; Bright lights at night emerge as new heart disease risk factor. 

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with James Cox, Professor of Cardiac Surgery at the Feinberg School of Medicine at Northwestern Medicine in Chicago, Illinois, USA, and Patrick McCarthy, Executive Director of the Bluhm Cardiovascular Institute, Heller-Sacks Professor of Cardiothoracic Surgery, Professor of Cardiac Surgery at the Feinberg School of Medicine at Northwestern Medicine in Chicago, Illinois, USA, about the surgical treatment of atrial fibrillation (AF). Chapters  00:00 Intro  01:32 CMS NCD on TAVR Heart Team  04:22 JANS 1, Tarlatamab Clinical Responses   05:23 JANS 2, No Stent Hybrid Revasc Robotic TECAB  06:45 JANS 3, STS Risk Model for SAVR After TAVR  08:43 JANS 4, Surgical Exposure Bilat Lung Transplant  10:12 JANS 5, Heart Drug Failure Challenges Theory  12:53 Video 1, Off-Pump TECAB da Vinci 5  14:00 Video 2, Aortic Uncrossing, Circumflex Aorta  14:50 Video 3, Ross Face-Off, Twin Root Replacement  15:57 Dr. Cox & McCarthy, Atrial Fib Surgery  27:00 Upcoming Events  They discussed the vital importance of surgical treatment for AF, the current underutilization of these procedures, the rationale for why AF should be treated, and abating AF. Furthermore, they explored the role of AF as a quality marker, the necessity for surgeons to develop proficiency in these techniques, and the importance of resident training on this procedure. Additionally, they reviewed the benefits of devices for AF, examined arrythmias in general, and their newly published textbook on the subject. Joel also highlights recent JANS articles on the Society of Thoracic Surgeons risk model for surgical aortic valve replacement after transcatheter aortic valve replacement, a promising heart drug failing which challenged a long-held theory of disease, clinical responses to tarlatamab among patients with pulmonary carcinoid, hybrid revascularization with robotic totally endoscopic coronary bypass and stents, and the effect of surgical exposure on outcomes in bilateral lung transplantation. In addition, Joel explores off-pump totally endoscopic coronary artery bypass using the da Vinci 5, aortic uncrossing procedure for circumflex aorta, and a twin root replacement combined with coronary artery bypass after a previous Ross procedure. Before closing, Joel highlights upcoming events in CT surgery. JANS Items Mentioned The Society of Thoracic Surgeons Risk Model for Surgical Aortic Valve Replacement After Transcatheter Aortic Valve Replacement A Promising Heart Drug Fails, Challenging a Long-Held Theory of Disease Clinical Responses to Tarlatamab Among Patients With Pulmonary Carcinoid Hybrid Revascularization With Robotic Totally Endoscopic Coronary Bypass and Stents: What Are the Outcomes When The Stent Does Not Happen? Effect of Surgical Exposure on Outcomes in Bilateral Lung Transplantation: Insight From the International Multicenter Extracorporeal Life Support in Lung Transplantation Registry CTSNet Content Mentioned Off-Pump Totally Endoscopic Coronary Artery Bypass Using the da Vinci 5: Closed-Chest Stabilizer Technique Aortic Uncrossing Procedure for Circumflex Aorta Ross “Face-Off”: Twin Root Replacement Other Items Mentioned Oral Board AI Simulator CTSNet Innovation Video Competition Career Center CTSNet Events   Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Commentary by Dr. Jian'an Wang.

To have your question featured in a future video, please visit: DrMorses.TV/ask Buy herbs: https://jo.my/handcrafted-formulas Getting Started Guide: https://jo.my/start-here-hbf

Description: In this episode of The Lead, host Jenelle Dziano, PhD candidate, is joined by Roopinder Sandu, MD, MPH, FHRS and Louise Segan, MBBS, MPH, PhD to discuss the journal article, Weight Loss in Older Patients With Persistent Atrial Fibrillation, The LOSE-AF Randomized Clinical Trial. Together, they review the findings of the LOSE-AF randomized clinical trial examining weight loss in older patients with persistent atrial fibrillation. Learning Objectives Review the key findings of the LOSE-AF randomized clinical trial examining weight loss in older patients with persistent atrial fibrillation. Discuss the role of weight loss in the management of older patients with persistent atrial fibrillation. Examine the clinical implications of the study findings for patients with persistent atrial fibrillation. Host: Jenelle Dziano, PhD candidate   Guests: Roopinder Sandu, MD, MPH, FHRS and Louise Segan, MBBS, MPH, PhD   Disclosures: J. Dziano No relevant disclosures R. Sandu No relevant disclosures L. Segan No relevant disclosures

Atrial Fibrillation, or AFib, is the most common cardiac arrhythmia (also known as an irregular heartbeat). AFib occurs when the upper chambers of the heart beat in an uncontrolled manner. The condition is currently on the rise, affecting more than 55 million people globally. AFib is a progressive disease, meaning that early diagnosis and treatment are imperative. Early intervention can make AFib easier to manage, help prevent it from worsening, and improve long-term outcomes.Become a supporter of this podcast: https://www.spreaker.com/podcast/arroe-collins-like-it-s-live--4113802/support.

Special edition of the JAMA Editor's Summary featuring the JAMA Network articles published at the 2026 European Society of Cardiology Congress. Hosted by JAMA Executive Editor Gregory Curfman, MD, with JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editors Gregg C. Fonarow, MD, and Paz Tayal, BMBCh, PhD. Related Content: Cardiovascular Magnetic Resonance to Guide Defibrillator Implantation for LVEF of 36% to 50% LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction Pulmonary Vein Isolation Using Pulsed Field Ablation With vs Without Posterior Wall Isolation in Patients With Symptomatic Persistent Atrial Fibrillation Digital Outreach to Improve Statin Refills in Patients With Low Statin Adherence Anticoagulation Monotherapy vs Antiplatelet Monotherapy After Transcatheter Aortic Valve Implant 124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy Low-Voltage Ablation in Persistent Atrial Fibrillation Electrocardiogram-Based Deep Learning to Prioritize Testing for Transthyretin Amyloid Cardiomyopathy Artificial Intelligence–Enabled Acquisition and Interpretation for Screening Aortic Stenosis Machine Learning–Driven Risk Prediction Model in Transthyretin Amyloid Cardiomyopathy Causal Endotype–Based Classification of Myocardial Infarction Prognostic Thresholds of Tricuspid Regurgitation in Transthyretin Amyloid Cardiomyopathy Periprocedural Mortality Risk After Elective Atrial Fibrillation Ablation in Japan Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer

In this episode of The Lead recorded at EHRA, host Christopher Kowalewski, MD, is joined by Tina Baykaner, MD, MPH, and Sanjiv M. Narayan, MD, PhD, FHRS, to discuss the journal article, Relationship Between Time-to-First Atrial Tachyarrhythmia Recurrence and Atrial Fibrillation Burden: Implications for Trial Design. Together, they examine the relationship between time to first atrial tachyarrhythmia recurrence and atrial fibrillation burden and discuss the implications of these measures for clinical trial design. Learning Objectives Review the relationship between time-to-first atrial tachyarrhythmia recurrence and atrial fibrillation burden. Discuss how different measures of atrial fibrillation recurrence and burden may influence the interpretation of clinical trial outcomes. Examine the implications of atrial fibrillation burden and time-to-first recurrence for the design of future atrial fibrillation trials.   Host: Christopher Kowalewski, MD   Guests: Tina Baykaner, MD, MPH and Sanjiv M. Narayan, MD, PhD, FHRS   Disclosures:   C. Kowalewski No relevant disclosures   T. Baykaner Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific Research: NIH, Boston Scientific   S. Narayan Honoraria/Speaking/Consulting Fee: UpToDate, Inc, LifeSignals, Abbott Medical, TDK Inc. Research: National Institutes for Health Intellectual Property Rights: University of California Regents Stocks – Privately Held: Physcade

In this episode of The Lead recorded at HRS2026, host Danesh Kella, MBBS, FHRS is joined by Jeffrey S. Healey, MD, FHRS and Fred M. Kusumoto, MD, FHRS to discuss the journal article, Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation (The CLOSURE-AF Trial). Together, they review the study findings comparing left atrial appendage closure with medical therapy in patients with atrial fibrillation and discuss the potential implications for clinical practice. Learning Objectives Review the design and key findings of the CLOSURE-AF Trial comparing left atrial appendage closure with medical therapy in patients with atrial fibrillation. Discuss the comparative considerations of left atrial appendage closure and medical therapy for the management of atrial fibrillation. Examine the potential clinical implications of the CLOSURE-AF Trial for treatment decision-making in patients with atrial fibrillation.   Host: Danesh Kella, MBBS, FHRS Guests: Jeffrey S. Healey, MD, FHRS and Fred M. Kusumoto, MD, FHRS   Disclosures: D. Kella Honoraria/Speaking/Consulting Fee: Zoll Medical Corporation, MBW Spectrum   J. Healey Honoraria/Speaking/Consulting Fee: Boston Scientific, Servier Research: Pfizer, Boston Scientific, Medtronic, Inc. Speakers' Bureau: Bristol-Myers Squibb   F. Kusumoto No relevant disclosures

Cardiologist and electrophysiologist Dr. Gregory Marcus, chair of the American Heart Association scientific statement writing group, reveals evidence on coffee/caffeine and cardiovascular health. He discusses how earlier assumptions that caffeine triggers arrhythmias are complicated by genetics, individual risk factors, and mostly observational research. Marcus reviews randomized and observational findings: the CRAVE trial showed no increase in premature atrial contractions but more premature ventricular contractions on coffee days; a trial in post-cardioversion patients found less atrial fibrillation with daily coffee. Observational data suggest lower risks of type 2 diabetes, heart attack, stroke, and AFib among coffee drinkers, while heart failure risk may be lower at low intake but higher around 4–5 drinks/day. He cautions against extrapolating benefits to energy drinks, discusses additives like sugar, touches on alcohol, cannabis, Mediterranean/DASH diets, pollution, and evolving AFib treatments, wearables, and pacing/ablation technologies.

Please visit answersincme.com/860/103760795-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Keith C. Ferdinand, MD; Mike Sharma, MD, MSc; and Eddie Needham, MD, FAAFP. In this activity, experts in atrial fibrillation (AF) discuss evidence-based strategies to optimize stroke prevention, address anticoagulation gaps in clinical practice, and prepare for emerging approaches to anticoagulation. Upon completion of this activity, participants should be better able to: Apply evidence-based risk stratification tools and guidelines to address anticoagulation gaps in primary care patients with AF; Assess the clinical impact of suboptimal anticoagulation on AF stroke prevention; Evaluate emerging strategies for AF stroke prevention, including factor XI/XIa inhibitors; and Outline multidisciplinary, equity-focused care strategies incorporating social determinants to optimize AF stroke prevention in diverse populations.

Commentary by Dr. Duk-Woo Park.

This week we speak with Dr. Ted O'Leary, Co-Director of Adult Congenital Heart Disease Electrophysiology at Boston Children's Hospital about a recent publication he authored on the use of pulsed field ablation (PFA) for the transcatheter ablation management of complex atrial arrhythmias in ACHD patients. How does PFA work and what are some of the potential advantages and disadvantages of this novel ablation energy technology? What are the advantages of a variable loop catheter in this setting? Is PFA going to supplant radiofrequency current for standard "SVT" ablations one day? These are amongst the questions reviewed with Dr. O'Leary this week. DOI: 10.1161/CIRCEP.125.014619

The new vaccine schedule recommendationsMy urologist is giving me grief that my vitamin D level is too highWhich nattokinase do you recommend to treat long covid?Is the vitamin K in your bone protocol different from the heart protocol?What about methylated B vitamins for brain vs. heart health?

Commentary by Dr. Panteleimon Papakonstantinou.

Send Zorba a message!Zorba opens up about his recent surgery, and what led to it. He helps a caller with a question about dealing with AI on health websites. He gives advice to a listener regarding liver health, discusses why the PSA test for prostate health is seen as controversial, and we hear from the pesky Grammar Cops.Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

Send Zorba a message!Zorba opens up about his recent surgery, and what led to it. He helps a caller with a question about dealing with AI on health websites. He gives advice to a listener regarding liver health, discusses why the PSA test for prostate health is seen as controversial, and we hear from the pesky Grammar Cops.Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

In this episode of The Lead, host Tina Baykaner, MD, MPH, is joined by Christopher Kowalewski, MD, and Marco Perez, MD, to discuss the journal article, Atrial Fibrillation Screening According to Genetic Risk: A Secondary Analysis of the Randomized LOOP Study. Together, they review findings from this secondary analysis of the LOOP Study and explore the relationship between genetic risk and atrial fibrillation screening. Learning Objectives Review the key findings from the secondary analysis of the randomized LOOP Study examining atrial fibrillation screening according to genetic risk. Discuss the relationship between genetic risk and atrial fibrillation screening as evaluated in the study. Explore the potential implications of incorporating genetic risk into atrial fibrillation screening strategies.   Host: Tina Baykaner, MD, MPH Guests: Christopher Kowalewski, MD and Marco Perez, MD   Disclosures: T. Baykaner Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific Research: NIH, Boston Scientific   C. Kowalewski No relevant disclosures   M. Perez Ownership/Partnership/Principal: QALY Honoraria/Speaking/Consulting Fee: Boston Scientific, Biotronik Research: Apple, Inc. Other/Stock Options Privately Held

Recorded at EHRA 2026, this episode of The Lead features host Christopher Kowalewski, MD, in conversation with Christian Sohns, MD, and Pierre Jaïs, MD, about the journal article, 20 Years: Clinical Outcome After Pulmonary Vein Isolation in Patients With Symptomatic Drug-Refractory Paroxysmal Atrial Fibrillation. Together, they discuss the study's long-term clinical outcomes following pulmonary vein isolation in patients with symptomatic drug-refractory paroxysmal atrial fibrillation and explore the implications of two decades of follow-up.   Learning Objectives: Review the long-term clinical outcomes reported after pulmonary vein isolation in patients with symptomatic drug-refractory paroxysmal atrial fibrillation. Discuss the implications of 20-year follow-up data for the treatment of patients undergoing pulmonary vein isolation. Examine how long-term outcome data may inform clinical decision-making for catheter ablation in paroxysmal atrial fibrillation.   Host: Christopher Kowalewski, MD   Guests: Christian Sohns, MD and Pierre Jaïs, MD   Disclosures: C. Kowalewski No relevant disclosures   C. Sohns No relevant disclosures   P. Jaïs Ownership/Partnership/Prinicipal: inHEART Honoraria/Speaking/Consulting Fee: Biosense Webster, Inc., Boston Scientific, Medtronic

Recorded at EHRA 2026, this episode of The Lead features host Michael S. Lloyd, MD, FHRS, in conversation with Tina Baykaner, MD, MPH, and Kenneth Ellenbogen, MD, FHRS, about the journal article, Real-time smartphone alerts during atrial fibrillation episodes with implantable cardiac monitors and wearable devices: SMART-ALERT study. Together, they discuss the study findings and explore the use of real-time smartphone alerts in conjunction with implantable cardiac monitors and wearable devices during atrial fibrillation episodes. Learning Objectives Review the design and key findings of the SMART-ALERT study evaluating real-time smartphone alerts during atrial fibrillation episodes. Discuss the use of implantable cardiac monitors and wearable devices for real-time detection and notification of atrial fibrillation episodes. Explore the potential clinical implications of integrating smartphone alerts with cardiac monitoring technologies.   Host: Michael S. Lloyd, MD, FHRS   Guests: Tina Baykaner, MD, MPH Kenneth A. Ellenbogen, MD, FHRS   Disclosures: M. Lloyd ·      Honoraria/Speaking/Consulting Fee: Medtronic, Boston Scientific, Other   T. Baykaner ·      Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific ·      Research: NIH, Boston Scientific   K. Ellenbogen ·      Honoraria/Speaking/Consulting Fee: American College of Cardiology, Heart Rhythm Society, Boston Scientific, Medtronic, Inc., Abbott ·      Royalty Income: Wiley-Blackwell, Elsevier

In this episode of the Heart podcast, Digital Media Editor, Professor James Rudd, is joined by Dr Emma Svennberg from Karolinska Hospital in Stockholm, Sweden. They discuss her review on AF screening and dive into why many trials have been disappointing and how things might improve in the future. If you enjoy the show, please leave us a positive review wherever you get your podcasts. It helps us to reach more people - thanks! Link to published paper: https://heart.bmj.com/content/early/2026/02/26/heartjnl-2025-326121  

Pulsed Field Ablation for Atrial Fibrillation with Left Atrial Appendage Occlusion   Guest: Ammar Killu, M.B.B.S. Host: Anthony Kashou, M.D.   In this episode of Interviews with the Expert: ECG Making Waves, host Dr. Anthony Kashou is joined by Dr. Ammar Killu to discuss the evolving role of combining pulsed field ablation (PFA) with left atrial appendage occlusion (LAAO) for patients with atrial fibrillation. Together, they explore the rationale for a combined approach, the potential advantages of PFA over conventional thermal ablation, and key procedural considerations for performing both interventions safely and effectively in a single session.   Topics Discussed: Why consider combining pulsed field ablation and left atrial appendage occlusion in the same AF patient? What does PFA add compared with conventional thermal ablation when planning a combined ablation–LAAO strategy? What are the procedural caveats when PFA and LAAO are done concomitantly?   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode.   Podcast episode transcript found here.   Recorded on: 26-June-2026  

Is it safe to stop statins “cold turkey”? Can the supplement ingredient HMB counteract age-related muscle loss? Researchers may have discovered the key to development of a true fat-burning weight loss medication; Can a mammogram yield clues about cardiovascular risk? Their bottom line threatened by GLP-1 weight loss drugs, BIg Food tweaks portion sizes, adds spices and flavorings to pique blunted appetites; Vitamins A & D may improve lung health for asthma sufferers; When it comes to thyroid medication prescribing, treat the numbers or treat the patient? 

Send Zorba a message!Zorba looks at research linking a drop in U.S. birthrates to the release of the iPhone. Zorba describes his experience singing a song with Karl's band, and talks about how trying new things out of your comfort zone is good for your health. He also helps a caller with toenail fungus, and another listener with atrial fibrillation (AFib) questions. We also hear a joke from Karl's mom, discuss new SNAP benefits policy changes, and talk about "zig-zag eating."Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

Send Zorba a message!Zorba looks at research linking a drop in U.S. birthrates to the release of the iPhone. Zorba describes his experience singing a song with Karl's band, and talks about how trying new things out of your comfort zone is good for your health. He also helps a caller with toenail fungus, and another listener with atrial fibrillation (AFib) questions. We also hear a joke from Karl's mom, discuss new SNAP benefits policy changes, and talk about "zig-zag eating."Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

With Boyoung Joung, Yonsei University, Seoul - Korea and Taehyun Hwang, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul - Korea. Link to European Heart Journal paper Link to European Heart Journal editorial

CBD may slow Alzheimer's progression by tamping down brain inflammation; Fifty million dollar settlement in Gardasil Classic action; Urethral stricture as a side effect of ablation for enlarged prostate; Zero-sugar diet may have unanticipated adverse health consequences; Are there drug-free alternatives for atrial fibrillation? Can you reverse lactose intolerance with a skin patch?

Join us for an informative discussion on Atrial Fibrillation (AFib), the most common type of irregular heart rhythm affecting millions of people worldwide. Learn how to recognize the signs and symptoms, understand potential risk factors and complications, and explore the latest treatment options available. Whether you've been diagnosed with AFib, care for someone who has it, or simply want to learn more about heart health, this episode provides valuable insights to help you take charge of your cardiovascular well-being.

In this episode of The Lead, host Christopher Kowalewski, MD, is joined by John M. Mandrola, MD, and Nassir F. Marrouche, MD, FHRS, to discuss the journal article, The Association Between Atrial Fibrillation Burden and Quality of Life: A Substudy of the SHAM-PVI Trial. Together, they explore the relationship between atrial fibrillation burden and quality of life, reviewing findings from this substudy of the SHAM-PVI Trial and discussing their relevance to patient-centered outcomes. Learning Objectives Review the key findings from the SHAM-PVI Trial substudy examining the association between atrial fibrillation burden and quality of life. Discuss the relationship between atrial fibrillation burden and patient-reported quality-of-life outcomes. Explore the implications of assessing both arrhythmia burden and quality of life when evaluating treatment outcomes in atrial fibrillation.   Host: Christopher Kowalewski, MD Guests: John M. Mandrola, MD and Nassir F. Marrouche, MD, FHRS   Disclosures: Christopher Kowalewski, MD No relevant disclosures   John M. Mandrola, MD No relevant disclosures   Nassir F. Marrouche, MD, FHRS •       Honoraria/Speaking/Consulting Fee/Speaker's Bureau: Biosense Webster, Inc., Boston Scientific, AtriCure, Inc., Abbott, Sanofi •       Research: Abbott, Biosense Webster, Inc., Medtronic, Siemens, General Electric, Boston Scientific, Sanofi, Samsung

In this episode of The Cardiac Recovery Room, moderator Dr. Rawn Salenger, Chief of Cardiac Surgery at the University of Maryland St. Joseph Medical Center, engages in a conversation with Dr. Shuba Chatterjee, Associate Professor of Surgery and Director of Thoracic Surgical ICU and ECMO Program at Baylor College of Medicine in Houston, TX, USA, and nurse practitioner Amanda Rea, Lead of Advanced Practice and Clinical Program Manager in the Division of Cardiac Surgery at the University of Maryland St. Joseph Medical Center in Townson, MD, USA. Their conversation focused on hemodynamics and atrial fibrillation. Chapters  00:00 Intro  01:17 Vasoplegia/Vasodilatory Shock  06:13 Vasopressors, Cost Considerations  07:32 Vasoplegia Misconceptions  08:41 Defining Vasoplegia  10:54 Blood Pressure Target Variable  12:54 Inotropes  17:03 Approach to Atrial Fibrillation  19:08 Patient Monitoring  19:27 Surgical/Concomitant Ablation  23:13 Postop AFib, Preventive Strategies  28:37 Example Scenario, High Heart Rate  29:56 Out of AFib Into Sinus Rhythm  33:01 Anticoagulation  39:43 Key Points  Key topics include vasoplegia, vasodilatory shock, and the use of vassopressors, including norepinephrine. They address common misconceptions surrounding vasoplegia shock, the role of epinephrine, and the use of methylene blue. Their conversation further delves into approaches for atrial fibrillation, concomitant surgical ablation, and postoperative atrial fibrillation. They highlight the best preventative strategies for atrial fibrillation and the use of beta blockers for atrial fibrillation. Finally, they discuss current guidelines and the role of anticoagulation in patients with atrial fibrillation. The Cardiac Recovery Room is the place to hear the conversations colleagues are having after the meetings. Each month, a new episode will be released featuring a leadership panel from the ERAS Cardiac Society.   Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Deprescribing thyroid and other meds in older adultsCan I safely take serrapeptase for longer than four weeks?I want to take nattokinase but isn't there a 'clot dislodging' risk?Could you discuss C. difficile and how to treat it?

In this episode of The Lead, host Christopher C. Cheung, MD, MPH, FHRS, is joined by Edward P. Gerstenfeld, MD, MS, FHRS, and Paul C. Zei, MD, PhD, FHRS, to discuss the journal article, A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation versus Anti-Arrhythmic Drug Therapy as a First Line Treatment for Persistent Atrial Fibrillation (AVANT GUARD). Together, they review the study design and findings, examining pulsed field ablation and anti-arrhythmic drug therapy as first-line treatment approaches for patients with persistent atrial fibrillation. Learning Objectives Review the design and key findings of the AVANT GUARD study comparing pulsed field ablation with anti-arrhythmic drug therapy as first-line treatment for persistent atrial fibrillation. Discuss the potential role of pulsed field ablation as an initial treatment strategy for patients with persistent atrial fibrillation. Examine the comparative considerations of ablation-based and pharmacologic approaches in the management of persistent atrial fibrillation.   Podcast Contributors: Host: Christopher C Cheung, MD, MPH, FHRS       Guests: Edward P. Gerstenfeld, MD, MS, FHRS and Paul C Zei, MD, PhD, FHRS   Disclosures: Christopher C Cheung, MD, MPH, FHRS Honoraria/Speaking/Consulting Fee: Medtronic, Inc., Biotronik, Biosense Webster, Inc., Abbott Edward P. Gerstenfeld, MD, MS, FHRS Honoraria/Speaking/Consulting Fee: Medtronic, Inc., Biosense Webster, Inc., Abbott, Boston Scientific, Varian Medical Systems Other Non-Financial Relationships: Adagio Medical, Boston Scientific, Abbott Medical Research: Abbott Medical Officer, Trustee, Director, Committee Chair, or Other Fiduciary Role: American College of Cardiology Paul C Zei, MD, PhD, FHRS Honoraria/Speaking/Consulting Fee/Speaker's Bureau: Varian Medical Systems, Biosense Webster, Inc., Abbott, Boston Scientific, APT Medical Research: Biosense Webster, Inc.

Can topical B12 help relieve itching?The types of doctors to avoidGetting back to basicsA case study of lavender oil helping to relieve itchingYou say you're dairy sensitive but you use whey protein. Please explain.What are your thoughts on a lactose relief patch that is on offer?

In this episode of The Lead, host Sandeep A. Saha, MD, MS, FHRS, is joined by Babak Nazer, MD, and Rajesh Kabra, MD, FHRS, to discuss the journal article, Safety and Effectiveness of a Dual-Energy Focal Ablation Catheter to Treat Paroxysmal Atrial Fibrillation: 6-Month Results of the FlexPulse IDE Study. Together, they review the study's six-month findings and explore the safety and effectiveness of a dual-energy focal ablation catheter for the treatment of paroxysmal atrial fibrillation. Learning Objectives Review the six-month results of the FlexPulse IDE Study evaluating a dual-energy focal ablation catheter for the treatment of paroxysmal atrial fibrillation. Discuss the safety outcomes reported in the study and their implications for clinical practice. Examine the effectiveness findings of the dual-energy focal ablation approach in patients with paroxysmal atrial fibrillation. Podcast Contributors Sandeep A Saha, MD, MS, FHRS  Babak Nazer, MD Rajesh Kabra, MD, FHRS   Host and Contributor Disclosure(s): S. Saha• Honoraria/Speaking/Consulting Fee/Speaker's Bureau: Medtronic, Inc. B. Nazer •Honoraria/Speaking/Consulting Fee: Edwards Lifesciences, Biosense Webster, Inc., Siemens Healthineers •Research: Siemens Healthineers R. Kabra •Honoraria/Speaking/Consulting Fee: AtriCure, Inc., Biosense Webster, Inc., Milestone Pharmaceuticals, AltaThera Pharmaceuticals •Research: Abbott Medical, Medtronic, Inc.  

In this episode of The Lead, host Melissa Middeldorp, MPH, PhD, FHRS is joined by Jenelle Dziano, PhD candidate, Clinical Exercise Physiologist and Adrian D. Elliott, PhD for a discussion of the recent journal article, Exercise Capacity and Quality-of-Life Improvements after Catheter Ablation in Patients with Clinically Asymptomatic Persistent Atrial Fibrillation. Together, they explore the study findings and discuss the impact of catheter ablation on exercise capacity and quality of life in patients with clinically asymptomatic persistent atrial fibrillation. Learning Objectives Review the key findings from the journal article examining exercise capacity and quality-of-life outcomes after catheter ablation in patients with clinically asymptomatic persistent atrial fibrillation. Discuss the potential clinical implications of catheter ablation for patients who may not report traditional atrial fibrillation symptoms. Explore the role of exercise capacity and quality-of-life measures in evaluating treatment outcomes for persistent atrial fibrillation. Podcast Contributors: Host: Melissa Middeldorp, MPH, PhD, FHRS Guests: Jenelle Dziano, PhD candidate, Clinical Exercise Physiologist and Adrian D. Elliott, PhD Host and Contributor Disclosure(s): M. Middeldorp: Nothing to disclose J. Dziano: Nothing to disclose A. Elliiott: Nothing to disclose

In this episode, CardioNerds Dr. Colin Blumenthal, Dr. Kelly Arps, and Dr. Yong Hao Yeo are joined by electrophysiology expert Dr. Bradley Knight to discuss atrial fibrillation (AF) management in challenging clinical scenarios. We explore arrhythmias in patients with pre-excitation syndromes, particularly Wolff-Parkinson-White (WPW) syndrome, and strategies for rhythm control. We also discuss AF management in pregnancy, adult congenital heart disease, and patients with tachycardia-bradycardia (tach-brady) syndrome. This episode provides essential insights into nuanced decision-making for the care of patients with complex arrhythmia profiles. Audio editing by CardioNerds academy intern, Grace Qiu. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Atrial Fibrillation PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! PEARLS AF in WPW is a true emergency—AV nodal blocking agents can be deadly. In patients with WPW syndrome, AF can rapidly conduct through the accessory pathway, risking ventricular fibrillation and sudden death. Avoid AV nodal blockers like beta-blockers and calcium channel blockers. Catheter ablation is the first-line rhythm control strategy in WPW. Catheter ablation carries a Class I recommendation and offers >90% success. If antiarrhythmic drugs are needed, sodium channel blockers like flecainide or propafenone are preferred in patients without structural heart disease. In pregnancy, protecting the mother is protecting the fetus. An unstable mother means an unstable fetus. Rate control is the first step in AF with rapid ventricular responses and electrical cardioversion is safe when needed. Multidisciplinary care is essential. AF in congenital heart disease is often outside the pulmonary veins. Surgical scars and chamber remodeling in ACHD patients often lead to AF from non-pulmonary vein foci. Electrogram-based mapping and targeted ablation strategies are essential to increase success rate of durable rhythm control. Tachy-brady syndrome may require pacing to unlock therapy. AF may cause atrial myopathy and sinus node dysfunction. These patients often require permanent pacing to allow safe use of rate-controlling medications like beta-blockers and to prevent syncope or chronotropic incompetence. Notes: Notes drafted by Dr. Yong Hao Yeo Why is atrial tachycardia in patients with WPW syndrome dangerous? Patients with WPW commonly present with supraventricular tachycardia (SVT) due to atrioventricular reentrant circuits, either orthodromic or antidromic. This SVT can degenerate into AF. In the absence of AV nodal as the governor between the atrium and ventricles, the accessory pathway may conduct impulses rapidly and frequently. This can lead to dangerously high ventricular rates, predisposing patients to ventricular fibrillation and sudden cardiac arrest. What are some strategies for rhythm control in patients with WPW and atrial tachycardia? Catheter ablation is the first-line therapy (Class I recommendation), with a success rate of over 90%. Ablation reduces the risk of sudden cardiac arrest, though some patients may remain prone to AF. If ablation is not feasible/ contraindicated, sodium channel blockers such as flecainide and propafenone are good options in patients without ischemia or structural heart disease (Class IIa recommendation). Amiodarone should be avoided because it has a long half-life, can accumulate in the system, and may delay definitive treatment with catheter ablation. AV nodal blocking agents like beta blockers and calcium channel blockers should be avoided, as they are less effective at controlling ventricular rate in WPW and can increase conduction over the accessory pathway. These agents can also exacerbate the risk of rapid ventricular rates during AF and worsen left ventricular function. What are some special considerations in managing AF in pregnant patients? The primary goal in managing cardiovascular disease during pregnancy is to protect the mother, as fetal outcomes depend on maternal well-being. Therefore, while caution is necessary, we should avoid undertreating pregnant patients with AF. In cases of AF with rapid ventricular response (RVR), rate control is usually the first-line strategy, with beta blockers preferred over digoxin or non-dihydropyridine calcium channel blockers. It is then reasonable to initially observe for spontaneous conversion in stable patients. Antiarrhythmic drugs (AADs) are generally avoided during the first trimester, but clinical judgment on a case-by-case basis is essential. Evidence for the safety of AADs in pregnancy is limited, often derived from their use in other conditions such as fetal SVT. Flecainide and sotalol are reasonable options for rhythm control (Class IIa recommendation). Electrical cardioversion is considered safe in pregnancy and should be utilized when indicated (Do not forget!). There is no pregnancy-specific thromboembolic risk stratification tool. CHA₂DS₂-VASc scoring and the presence of risk factors like mitral stenosis can help guide anticoagulation decisions, though the magnitude of thromboembolic risk during pregnancy remains unclear. Rate control agents are typically continued during delivery due to the increased physiologic stress of labor and delivery. Multidisciplinary care is crucial and should involve obstetrics, maternal-fetal medicine, cardiology, and electrophysiology specialists. What are some key considerations for AF management in patients with adult congenital heart disease (ACHD)? Patients with repaired congenital heart disease are at increased risk for arrhythmias due to two main factors: surgical scars that create arrhythmogenic foci and mechanical remodeling of the atria or ventricles resulting from the underlying disease. In these patients with structural heart disease, sodium channel blockers may not be ideal antiarrhythmic options. When selecting an antiarrhythmic drug, clinicians must consider the nature of structural or surgical impairments, such as right bundle branch block or prolonged QT interval. It is also essential to assess renal and hepatic function (often impaired in patients with ACHD) to ensure appropriate metabolism and clearance of antiarrhythmic medications. Electrogram-based ablation strategies (those leveraging artificial intelligence are developing!) may help identify effective ablation targets, which are often outside the pulmonary veins in patients with ACHD. These individualized approaches can improve ablation success rates in this complex patient population. What makes tachycardia-bradycardia (tach-brady) syndrome a unique challenge in arrhythmia management? Patients who present with both AF and bradycardia, especially with syncope, require a thoughtful diagnostic approach to identify the underlying rhythm disturbance. Extended cardiac monitoring, including event monitors or implantable loop recorders, can help capture intermittent arrhythmias and correlate them with symptoms. AF may lead to atrial myopathy, and since the sinus node resides within the atrium, this can result in sinus node dysfunction—a hallmark of tachy-brady syndrome. Following spontaneous conversion from AF to sinus rhythm, sinus node dysfunction may persist, leading to prolonged pauses or chronotropic incompetence. Management becomes more complex when beta-blockers are needed for AF with RVR, as they can exacerbate bradycardia. Permanent pacemaker implantation is often the next step to consider. Permanent pacemaker implantation is often considered to facilitate safe rate control in these cases. In younger patients, aggressive AF burden reduction may prevent atrial remodeling and the development of true atrial myopathy, potentially avoiding pacemaker implantation. References Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2023;149(1). doi:https://doi.org/10.1161/CIR.0000000000001193 ‌ Van IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2024;45(36). doi:https://doi.org/10.1093/eurheartj/ehae176 ‌ Joglar JA, Kapa S, Saarel EV, et al. 2023 HRS expert consensus statement on the management of arrhythmias during pregnancy. Heart Rhythm. Published online May 1, 2023. doi:https://doi.org/10.1016/j.hrthm.2023.05.017 ‌ Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary. Journal of the American College of Cardiology. 2019;73(12):1494-1563. doi:https://doi.org/10.1016/j.jacc.2018.08.1028 ‌

This April 2026 Heart Rhythm Journal publication reports a sub-analysis of the CHAMPION-AF trial evaluating left atrial appendage closure (LAAC) versus oral anticoagulation in patients with atrial fibrillation who previously underwent catheter ablation. The analysis demonstrated that LAAC with the WATCHMAN FLX device provided comparable protection against stroke, systemic embolism, and cardiovascular death when compared with NOAC therapy, while also reducing long-term non-procedural bleeding events. These findings support consideration of LAAC as an alternative stroke prevention strategy in selected post-ablation AF patients through individualized, shared decision-making. Digital Education Committee Member Danesh Kella, MBBS, FHRS discusses this article from the Heart Rhythm Journal that preceded the Heart Rhythm 2026 Late-Breaking Clinical Trial. He is joined in the conversation by Jason T. Jacobson, MD, FHRS, Ammar M. Killu, MBBS, and Gregory M. Marcus, MD, FHRS.   Learning Objectives Describe the rationale for left atrial appendage closure as an alternative to chronic oral anticoagulation in patients with atrial fibrillation after catheter ablation. Review the efficacy and safety outcomes from the CHAMPION-AF sub-analysis comparing LAAC and NOAC therapy in post-ablation AF patients.  Discuss patient selection considerations and the role of shared decision-making when choosing stroke prevention strategies following AF ablation.    Podcast Contributors Danesh Kella, MBBS, FHRS Jason T. Jacobson, MD, FHRS Ammar M. Killu, MBBS Gregory M. Marcus, MD, FHRS    Host and Contributor Disclosure(s): J.T. Jacobson •Board/Advisory Committee Membership: Abbott Medical •Honoraria/Speaking/Teaching/Consulting: Zoll Medical Corporation, Vektor Medical, Inc. •Research: CardioFocus, Inc., Johnson and Johnson •Stocks, Privately Held: Atlas 5D D. Kella •Honoraria/Speaking/Teaching/Consulting: Zoll Medical Corporation, MBW Spectrum A. Killu •Board/Advisory Committee Membership: Boston Scientific •Honoraria/Speaking/Teaching/Consulting: AtriCure, Inc., Abbott, Biosense Webster, Inc., Siemans Healthineers •Research: Boston Scientific, Access Point Technologies G.M. Marcus •Honoraria/Speaking/Teaching/Consulting: InCarda Therapeutics •Research: NIH, PCORI, TRDRP •Stocks, Publicly Traded: InCarda Therapeutics  

This late-breaking sub-analysis from the CHAMPION-AF trial evaluated outcomes of left atrial appendage closure (LAAC) with the WATCHMAN FLX device versus oral anticoagulation in patients with atrial fibrillation who had previously undergone catheter ablation. Investigators found that LAAC provided similar protection against stroke, cardiovascular death, and systemic embolism compared with non-vitamin K oral anticoagulants (NOACs), while significantly reducing non-procedural bleeding events, regardless of prior ablation status. These findings suggest LAAC may be a viable alternative to long-term anticoagulation in select post-ablation AF patients through a shared decision-making approach. Join Digital Education Committee member Sandeep A. Saha, MD, MS, FHRS and his colleagues Scott C. Brancato, MD, FHRS and Rakesh Gopinathannair, MBA, MD, FHRS for this late-breaking coverage from Heart Rhythm 2026 in Chicago!   Learning Objectives Review the rationale for left atrial appendage closure as an alternative to long-term oral anticoagulation in patients with atrial fibrillation following catheter ablation. Analyze the CHAMPION-AF sub-analysis outcomes comparing LAAC and NOAC therapy with respect to stroke prevention, cardiovascular outcomes, and bleeding risk. Discuss how these findings may influence patient selection and shared decision-making for stroke prevention strategies in post-ablation atrial fibrillation care.    Podcast Contributors Sandeep A. Saha, MD, MS, FHRS Scott C. Brancato, MD, FHRS Rakesh Gopinathannair, MBA, MD, FHRS    Host and Contributor Disclosure(s): S. Brancato Nothing to disclose. R. Gopinathannair Board/Advisory Committee Membership: Heart Rhythm Society, AltaThera Pharmaceuticals Honoraria/Speaking/Teaching/Consulting: Abbott, Johnson and Johnson, Boston Scientific, Sanofi S. Saha Board/Advisory Committee Membership: Medtronic Honoraria/Speaking/Teaching/Consulting: Medtronic 

This discussion reviews the late-breaking HRS 2026 study Total Fatal Adverse Events Following Atrial Fibrillation Ablation Reported in an FDA Mandatory Reporting System: A Matter of Concern? The TiFFANY Study, which examined fatal adverse event reports associated with atrial fibrillation ablation using data from the FDA MAUDE database. Faculty discuss the incidence and mechanisms of rare but serious complications across ablation technologies, including pulsed field ablation and thermal energy sources, and explore the implications for procedural safety, post-market surveillance, and clinical decision-making in AF ablation. Join host Melissa E. Middeldorp, MPH, PhD and her esteemed guests Christopher F. Liu, MD, FHRS and James Freeman, MD, MPH, Msci for this late-breaking coverage from Heart Rhythm 2026 in Chicago! Learning Objectives Describe the methodology and key findings of the TiFFANY study evaluating fatal adverse events following atrial fibrillation ablation. Compare reported safety signals and complication profiles among pulsed field ablation and traditional thermal ablation technologies. Assess the role and limitations of post-market adverse event databases in evaluating procedural safety and informing electrophysiology practice.  Podcast Contributors Melissa E. Middeldorp, MPH, PhD, FHRS Christopher F. Liu, MD, FHRS James Freeman, MD, MPH, Msci  Host and Contributor Disclosure(s): D.C. Raja Nothing to disclose. A. Deshmukh Honoraria/Speaking/Teaching/Consulting: GE Healthcare, Biotronik, Medtronic, Biosense Webster Research: AltaThera Pharmaceuticals P. Lim Nothing to disclose.  

Research Examines the Connection Between Periodontitis and Atrial Fibrosis in Atrial FibrillationBy Today's RDH ResearchOriginal article published on Today's RDH: https://www.todaysrdh.com/research-examines-the-connection-between-periodontitis-and-atrial-fibrosis-in-atrial-fibrillation/Need CE? Start earning CE credits today at ⁠⁠⁠https://rdh.tv/ce⁠⁠⁠ Get daily dental hygiene articles at ⁠⁠⁠https://www.todaysrdh.com⁠⁠⁠ Follow Today's RDH on Facebook: ⁠⁠⁠https://www.facebook.com/TodaysRDH/⁠⁠⁠Follow Kara RDH on Facebook: ⁠⁠⁠https://www.facebook.com/DentalHygieneKaraRDH/⁠⁠⁠Follow Kara RDH on Instagram: ⁠⁠⁠https://www.instagram.com/kara_rdh/⁠

New cardiovascular data suggest pulsed field ablation may challenge antiarrhythmic drugs as first-line therapy for persistent atrial fibrillation, while real-world evidence positions apixaban as the preferred DOAC for younger patients with nonvalvular AF due to superior safety and effectiveness. Additional findings from the SENIOR-RITA trial indicate that routine invasive management may not benefit frail older adults with NSTEMI and could worsen outcomes in the most frail patients. Together, these studies highlight a growing shift toward more individualized cardiovascular treatment strategies.